{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:46:59Z","timestamp":1782316019149,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00120-024-02420-5","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T16:02:26Z","timestamp":1723651346000},"page":"985-993","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Kann beim muskelinvasiven Urothelkarzinom der Harnblase zuk\u00fcnftig auf die Zystektomie verzichtet werden?","Can muscle invasive bladder cancer be treated without cystectomy in the future?"],"prefix":"10.1007","volume":"63","author":[{"given":"Jan","family":"Hausmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla M.","family":"Grunewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"2420_CR1","first-page":"CD005246","volume":"2004","author":"C Advanced Bladder Cancer Overview","year":"2005","unstructured":"Advanced Bladder Cancer Overview\u00a0C (2005) Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev 2004:CD5246","journal-title":"Cochrane Database Syst Rev"},{"key":"2420_CR2","doi-asserted-by":"crossref","unstructured":"Balar AV, Milovsky MI, O\u2019Donnell PH, Alva AS et\u00a0al (2021) Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A\u00a0multicenter phase\u00a02\u00a0trial. J\u00a0Clin Oncol 39:","DOI":"10.1200\/JCO.2021.39.15_suppl.4504"},{"key":"2420_CR3","doi-asserted-by":"crossref","unstructured":"Ben-David R, Tillu N, Cumarasamy S et\u00a0al (2024) Longitudinal Tumor-informed Circulating Tumor DNA Status Predicts Disease Upstaging and Poor Prognosis for Patients Undergoing Radical Cystectomy. Eur Urol Oncol","DOI":"10.1016\/j.euo.2024.03.002"},{"key":"2420_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijrobp.2023.07.027","volume":"118","author":"K Bruck","year":"2024","unstructured":"Bruck\u00a0K, Meijer\u00a0RP, Boormans\u00a0JL et\u00a0al (2024) Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A\u00a0Nationwide Study. Int J Radiat Oncol Biol Phys 118:41\u201349","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2420_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","volume":"22","author":"A Choudhury","year":"2021","unstructured":"Choudhury\u00a0A, Porta\u00a0N, Hall\u00a0E et\u00a0al (2021) Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol 22:246\u2013255","journal-title":"Lancet Oncol"},{"key":"2420_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.18.00537","volume":"37","author":"JJ Coen","year":"2019","unstructured":"Coen\u00a0JJ, Zhang\u00a0P, Saylor\u00a0PJ et\u00a0al (2019) Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil\/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG\/RTOG 0712\u2014A Randomized Phase\u00a0II Trial. J\u00a0Clin Oncol 37:44\u201351","journal-title":"J Clin Oncol"},{"key":"2420_CR7","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.1996.14.11.2901","volume":"14","author":"CM Coppin","year":"1996","unstructured":"Coppin\u00a0CM, Gospodarowicz\u00a0MK, James\u00a0K et\u00a0al (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The national cancer institute of Canada clinical trials group. J\u00a0Clin Oncol 14:2901\u20132907","journal-title":"J Clin Oncol"},{"key":"2420_CR8","doi-asserted-by":"crossref","unstructured":"Culine S, Harter V, Krucker C et\u00a0al (2023) Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase\u00a0III VESPER (GETUG-AFU V05) Trial. Cancers 15:","DOI":"10.3390\/cancers15061742"},{"key":"2420_CR9","doi-asserted-by":"crossref","unstructured":"Ditonno F, Veccia A, Montanaro F et\u00a0al (2024) Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a\u00a0systematic review and meta-analysis of comparative studies. BJU Int","DOI":"10.1111\/bju.16366"},{"key":"2420_CR10","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1200\/JCO.2008.19.5776","volume":"27","author":"JA Efstathiou","year":"2009","unstructured":"Efstathiou\u00a0JA, Bae\u00a0K, Shipley\u00a0WU et\u00a0al (2009) Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99\u201306. J\u00a0Clin Oncol 27:4055\u20134061","journal-title":"J Clin Oncol"},{"key":"2420_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.eururo.2023.06.014","volume":"84","author":"TW Flaig","year":"2023","unstructured":"Flaig\u00a0TW, Tangen\u00a0CM, Daneshmand\u00a0S et\u00a0al (2023) Long-term Outcomes from a\u00a0Phase\u00a02 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Eur Urol 84:341\u2013347","journal-title":"Eur Urol"},{"key":"2420_CR12","doi-asserted-by":"publisher","first-page":"110038","DOI":"10.1016\/j.radonc.2023.110038","volume":"190","author":"G Francolini","year":"2024","unstructured":"Francolini\u00a0G, Ghoshal\u00a0A, Caini\u00a0S et\u00a0al (2024) Quality of life after definitive treatment for bladder cancer: A\u00a0systematic review and meta-analysis. Radiother Oncol 190:110038","journal-title":"Radiother Oncol"},{"key":"2420_CR13","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky\u00a0MD, Daneshmand\u00a0S, Izadmehr\u00a0S et\u00a0al (2023) Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a\u00a0phase\u00a02\u00a0trial. Nat Med 29:2825\u20132834","journal-title":"Nat Med"},{"key":"2420_CR14","doi-asserted-by":"crossref","unstructured":"Galsky MD, Daneshmand S, Lewis SC et\u00a0al (2023) Co-primary endpoint analysis of HCRN GU 16-257: Phase\u00a02\u00a0trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC). JCO 41:","DOI":"10.1200\/JCO.2023.41.6_suppl.447"},{"key":"2420_CR15","doi-asserted-by":"crossref","unstructured":"Geynisman DM, Abbosh P, Ross EA et\u00a0al (2023) A phase\u00a0II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN). JCO 41:","DOI":"10.1200\/JCO.2023.41.6_suppl.438"},{"key":"2420_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.euo.2023.02.008","volume":"6","author":"E Grobet-Jeandin","year":"2023","unstructured":"Grobet-Jeandin\u00a0E, Lenfant\u00a0L, Mir\u00a0C et\u00a0al (2023) A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer. Eur Urol Oncol 6:251\u2013262","journal-title":"Eur Urol Oncol"},{"key":"2420_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","volume":"82","author":"E Hall","year":"2022","unstructured":"Hall\u00a0E, Hussain\u00a0SA, Porta\u00a0N et\u00a0al (2022) Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase\u00a03 Randomised Controlled BC2001 Trial. Eur Urol 82:273\u2013279","journal-title":"Eur Urol"},{"key":"2420_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.eururo.2012.02.028","volume":"61","author":"RE Hautmann","year":"2012","unstructured":"Hautmann\u00a0RE, De Petriconi\u00a0RC, Pfeiffer\u00a0C et\u00a0al (2012) Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 61:1039\u20131047","journal-title":"Eur Urol"},{"key":"2420_CR19","doi-asserted-by":"crossref","unstructured":"Huddart RA, Hafeez S, Omar A et\u00a0al (2023) Randomised phase\u00a0II trial of adaptive image guided radiotherapy in muscle invasive bladder cancer: Late toxicity and cancer outcomes. JCO 41:","DOI":"10.1200\/JCO.2023.41.6_suppl.446"},{"key":"2420_CR20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1464-410X.2010.09537.x","volume":"106","author":"RA Huddart","year":"2010","unstructured":"Huddart\u00a0RA, Hall\u00a0E, Lewis\u00a0R et\u00a0al (2010) Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed. BJU Int 106:753\u2013755","journal-title":"BJU Int"},{"key":"2420_CR21","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.eururo.2019.11.001","volume":"77","author":"RA Huddart","year":"2020","unstructured":"Huddart\u00a0RA, Hall\u00a0E, Lewis\u00a0R et\u00a0al (2020) Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy \u00b1 Chemotherapy in the BC2001 Phase\u00a0III Randomised Controlled Trial. Eur Urol 77:260\u2013268","journal-title":"Eur Urol"},{"key":"2420_CR22","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.euf.2016.12.005","volume":"4","author":"JB Kukreja","year":"2018","unstructured":"Kukreja\u00a0JB, Porten\u00a0S, Golla\u00a0V et\u00a0al (2018) Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus 4:720\u2013724","journal-title":"Eur Urol Focus"},{"key":"2420_CR23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow\u00a0JJ, Martin-Doyle\u00a0W, Fay\u00a0AP et\u00a0al (2014) A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66:529\u2013541","journal-title":"Eur Urol"},{"key":"2420_CR24","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1200\/JCO.2003.05.101","volume":"21","author":"S Madersbacher","year":"2003","unstructured":"Madersbacher\u00a0S, Hochreiter\u00a0W, Burkhard\u00a0F et\u00a0al (2003) Radical cystectomy for bladder cancer today\u2014a homogeneous series without neoadjuvant therapy. J\u00a0Clin Oncol 21:690\u2013696","journal-title":"J Clin Oncol"},{"key":"2420_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.urology.2006.05.060","volume":"69","author":"M Milosevic","year":"2007","unstructured":"Milosevic\u00a0M, Gospodarowicz\u00a0M, Zietman\u00a0A et\u00a0al (2007) Radiotherapy for bladder cancer. Urology 69:80\u201392","journal-title":"Urology"},{"key":"2420_CR26","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.eururo.2019.12.016","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi\u00a0A, Bandini\u00a0M, Calareso\u00a0G et\u00a0al (2020) Multiparametric Magnetic Resonance Imaging as a\u00a0Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 77:636\u2013643","journal-title":"Eur Urol"},{"key":"2420_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","volume":"74","author":"V Panebianco","year":"2018","unstructured":"Panebianco\u00a0V, Narumi\u00a0Y, Altun\u00a0E et\u00a0al (2018) Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 74:294\u2013306","journal-title":"Eur Urol"},{"key":"2420_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","volume":"25","author":"C Pfister","year":"2024","unstructured":"Pfister\u00a0C, Gravis\u00a0G, Flechon\u00a0A et\u00a0al (2024) Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5\u00a0years in an open-label, randomised, phase\u00a03\u00a0study. Lancet Oncol 25:255\u2013264","journal-title":"Lancet Oncol"},{"key":"2420_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","volume":"66","author":"G Ploussard","year":"2014","unstructured":"Ploussard\u00a0G, Daneshmand\u00a0S, Efstathiou\u00a0JA et\u00a0al (2014) Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a\u00a0systematic review. Eur Urol 66:120\u2013137","journal-title":"Eur Urol"},{"key":"2420_CR30","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.eururo.2009.12.002","volume":"57","author":"VA Ramani","year":"2010","unstructured":"Ramani\u00a0VA, Maddineni\u00a0SB, Grey\u00a0BR et\u00a0al (2010) Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. Eur Urol 57:1058\u20131063","journal-title":"Eur Urol"},{"key":"2420_CR31","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","volume":"61","author":"R Rosenblatt","year":"2012","unstructured":"Rosenblatt\u00a0R, Sherif\u00a0A, Rintala\u00a0E et\u00a0al (2012) Pathologic downstaging is a\u00a0surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol 61:1229\u20131238","journal-title":"Eur Urol"},{"key":"2420_CR32","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.eururo.2017.03.038","volume":"72","author":"T Seisen","year":"2017","unstructured":"Seisen\u00a0T, Sun\u00a0M, Lipsitz\u00a0SR et\u00a0al (2017) Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder. Eur Urol 72:483\u2013487","journal-title":"Eur Urol"},{"key":"2420_CR33","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/j.ijrobp.2022.07.475","volume":"114","author":"P Singh","year":"2022","unstructured":"Singh\u00a0P, Efstathiou\u00a0JA, Plets\u00a0M et\u00a0al (2022) INTACT (S\/N1806): Phase\u00a0III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer\u2014Toxicity Update on First 213 Patients. Int J Radiat Oncol 114:S76\u2013S77","journal-title":"Int J Radiat Oncol"},{"key":"2420_CR34","doi-asserted-by":"publisher","first-page":"105032","DOI":"10.1016\/j.ebiom.2024.105032","volume":"101","author":"TAD Smith","year":"2024","unstructured":"Smith\u00a0TAD, West\u00a0CML, Joseph\u00a0N et\u00a0al (2024) A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial. eBioMedicine 101:105032","journal-title":"eBioMedicine"},{"key":"2420_CR35","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1200\/JCO.23.00725","volume":"41","author":"M Swinton","year":"2023","unstructured":"Swinton\u00a0M, Mariam\u00a0NBG, Tan\u00a0JL et\u00a0al (2023) Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer. J\u00a0Clin Oncol 41:4406\u20134415","journal-title":"J Clin Oncol"},{"key":"2420_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados\u00a0B, Kockx\u00a0M, Assaf\u00a0ZJ et\u00a0al (2022) Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol 82:212\u2013222","journal-title":"Eur Urol"},{"key":"2420_CR37","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.euf.2022.12.012","volume":"9","author":"G Tissot","year":"2023","unstructured":"Tissot\u00a0G, Xylinas\u00a0E (2023) Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Chemoradiotherapy Versus Chemoradiotherapy Alone in Muscle-invasive Bladder Cancer: The MK-3475-992\/KEYNOTE-992 Trial. Eur Urol Focus 9:227\u2013228","journal-title":"Eur Urol Focus"},{"key":"2420_CR38","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.ijrobp.2016.11.056","volume":"97","author":"V Vashistha","year":"2017","unstructured":"Vashistha\u00a0V, Wang\u00a0H, Mazzone\u00a0A et\u00a0al (2017) Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A\u00a0Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys 97:1002\u20131020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2420_CR39","doi-asserted-by":"crossref","unstructured":"Williams S, Cutie C, Keegan K et\u00a0al (2021) Sunrise-2: a\u00a0phase\u00a03, multicenter, randomized study evaluating the efficacy of tar-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder. J\u00a0Urol 206(suppl 3)","DOI":"10.1097\/JU.0000000000001994.17"},{"key":"2420_CR40","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta\u00a0AR, Ballas\u00a0LK, Niemierko\u00a0A et\u00a0al (2023) Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a\u00a0multi-institutional propensity score matched and weighted analysis. Lancet Oncol 24:669\u2013681","journal-title":"Lancet Oncol"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02420-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02420-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02420-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T05:02:26Z","timestamp":1728450146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02420-5"}},"subtitle":["Neue Daten zur trimodalen Therapie und zum Blasenerhalt nach reiner Systemtherapie","New data on trimodal therapy and bladder preservation after systemic therapy alone"],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2420"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02420-5","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"24 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Hausmann und C.M.\u00a0Grunewald geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}